Macquarie Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Macquarie Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.78M	Buy	+11,241	New	+$1.52M	0.01%	581
2025 Q4	–	Sell	-126	Closed	-$12.6K	–	1526
2025 Q3	$12.6K	Sell	126 -378	-75%	-$34K	﹤0.01%	1569
2025 Q2	$41.8K	Buy	504 +290	+136%	+$23.1K	﹤0.01%	1593
2025 Q1	$17.4K	Sell	214 -136	-39%	-$12.2K	﹤0.01%	1595
2024 Q4	$32	Sell	350 -610	-64%	-$59.1K	﹤0.01%	1651
2024 Q3	$94.8K	Sell	960 -120,803	-99%	-$11.9M	﹤0.01%	1584
2024 Q2	$11.3M	Buy	+121,763	New	+$10.9M	0.01%	789
2018 Q2	–	Sell	-12,600	Closed	-$1.1M	–	2284
2018 Q1	$1.1M	Sell	12,600 -15,939	-56%	-$1.46M	﹤0.01%	1154
2017 Q4	$2.42M	Buy	28,539 +15,939	+127%	+$1.34M	﹤0.01%	975
2017 Q3	$1.09M	Hold	12,600	–	–	﹤0.01%	1184
2017 Q2	$972K	Buy	+12,600	New	+$894K	﹤0.01%	1172

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Macquarie Group's XBI Position: Q2 2026 in Review

Macquarie Group opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 11,241 shares worth $1.78M. The stake represents 0.01% of the portfolio and ranks #581 among its holdings. This is a return to the name: Macquarie Group previously reported a position in XBI as recently as Q3 2025.

Macquarie Group first reported a position in XBI in Q2 2017 and has held it in 11 quarters since. The position peaked at $11.3M in Q2 2024. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Macquarie Group held 11,241 shares of State Street SPDR S&P Biotech ETF worth $1.78M as of Q2 2026.
State Street SPDR S&P Biotech ETF was a new Macquarie Group position in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.01% of Macquarie Group's portfolio in Q2 2026, its #581 holding.
Macquarie Group first reported a position in State Street SPDR S&P Biotech ETF in Q2 2017 and has held it in 11 quarters since.
Macquarie Group's State Street SPDR S&P Biotech ETF position peaked at $11.3M in Q2 2024.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Macquarie Group's 13F filing for Q2 2026, filed 14 Aug 2026.